Acrivon Therapeutics, Inc Common Stock
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -200 | -224 | ||
EBITDA | -24,651 | -25,140 | -21,437 | -17,444 |
EBIT | -24,954 | -25,391 | -21,665 | -17,668 |
Net Income | -22,831 | -22,441 | -18,798 | -16,486 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -18,187 | -18,312 | -14,040 | -17,898 |
Cash | 39,818 | 43,415 | 46,006 | 24,607 |
Basic Shares | 188,011 | 38,105 | 36,132 | 22,590 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -536 | -1,095 | -832 | |
EBITDA | -89,199 | -59,852 | -32,293 | -15,411 |
EBIT | -60,388 | -32,657 | -16,243 | |
Net Income | -80,556 | -60,388 | -29,677 | -16,243 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -70,084 | |||
Free Cash Flow | -68,437 | -43,929 | -32,283 | -14,220 |
Cash | 39,818 | 36,015 | 29,519 | 99,603 |
Basic Shares | 337,918 | 22,078 | 21,920 | 20,859 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.54 |
2024-09-30 | -$0.59 |
2024-06-30 | -$0.52 |
2024-03-31 | -$0.73 |
